NAGE - Latest News
Niagen Bioscience Inc (NAGE), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $205.5M. Trailing twelve-month P/E ratio is 12.80. Beta to the broader market is 2.02.
The article list below shows the most recent NAGE headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent NAGE Headlines
Niagen Bioscience (NASDAQ:NAGE) and Beauty Health (NASDAQ:SKIN) Head to Head Review
defenseworld.net - Oct 12, 2026
Beauty Health (NASDAQ: SKIN - Get Free Report) and Niagen Bioscience (NASDAQ: NAGE - Get Free Report) are both small-cap consumer staples companies, b
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
businesswire.com - Oct 8, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Award--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotid
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
businesswire.com - Oct 6, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
businesswire.com - Oct 1, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
businesswire.com - Sep 30, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
How News Affects NAGE Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NAGE's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked NAGE news questions
- What is the latest NAGE news headline?
- The most recent NAGE headline (Oct 12, 2026) is "Niagen Bioscience (NASDAQ:NAGE) and Beauty Health (NASDAQ:SKIN) Head to Head Review". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the NAGE news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What NAGE news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual NAGE options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.